Trials / Completed
CompletedNCT03727477
Efficacy of Treatment Sequences in Patients With Non-small Cell Lung Cancer Receiving Lorlatinib
Efficacy of Treatment Sequences in Patients With ALK and ROS-1 Positive Non-small Cell Lung Cancer Who Received Lorlatinib as Part of the French Expanded Access Program
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 291 (actual)
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study will evaluate progression-free survival, overall survival, best response and duration of treatment in patients with advanced ALK- and ROS1-positive non-small cell lung cancer who received lorlatinib as part of the French expanded access program.
Detailed description
IFCT-1803 LORLATU study will evaluate progression-free survival, overall survival, best response and duration of treatment in patients with advanced ALK- and ROS1-positive non-small cell lung cancer who received lorlatinib (PF-06463922) as part of the French expanded access program. Those outcomes will be correlated to clinical, pathological, and radiological characteristics of patients.
Conditions
- Non-small Cell Lung Cancer Metastatic
- ALK Gene Rearrangement Positive
- ROS-1 Gene Rearrangement Positive
Timeline
- Start date
- 2019-02-01
- Primary completion
- 2020-10-12
- Completion
- 2020-10-12
- First posted
- 2018-11-01
- Last updated
- 2023-05-24
Locations
30 sites across 1 country: France
Source: ClinicalTrials.gov record NCT03727477. Inclusion in this directory is not an endorsement.